Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLL
Jan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.
Jan Joseph Melenhorst Engineering Program Lerner Research Institute Precision Immuno Oncology Director Cell Therapy Immuno Engineering Program
Source: onclive.com